New Study Finds 88% of Medtechs Prioritizing Postmarket Quality Modernization Within Next 3 Years

Core Insights - The 2025 Veeva MedTech Postmarket Quality Benchmark Report indicates that 88% of surveyed medtech companies are advancing postmarket quality management within the next three years to enhance compliance and innovation [1][7] - A significant portion of medtech companies, 68%, still rely on manual processes, which can lead to delays in addressing product issues and backlogs in complaint handling [2][7] - The report highlights the need for proactive and risk-based quality management, with 38% of respondents identifying it as a primary driver for advancing quality [3] Industry Trends - There is a strong emphasis on technology as an enabler for quality management, with 75% of respondents believing that advanced technology can drive automation for faster timelines and efficiency [4] - Despite the potential benefits, generative AI and robotic process automation are scarcely adopted, with less than 3% of companies applying these technologies reliably [5] - Gaps in employee training are evident, as only 19% of respondents feel their training programs adequately support postmarket quality teams [6] Strategic Recommendations - Organizations are encouraged to align strategic goals with modern technology solutions to transition from reactive issue management to proactive risk prevention [7] - The report suggests that streamlining quality operations can lead to improved management and execution, particularly through proactive actions and scaling processes [3][4]